Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703702 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
A Phase 4 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 641
- Enrollment target
NCT01703702 is a Phase 4 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 641 participants.
The verdict
NCT01703702, a Phase 4 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 641 participants
- Enrollment target
Study Summary
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
Interventions
- DRUG florbetapir (18F)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703702
The ClinicalTrials.gov registry entry for NCT01703702 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which florbetapir (18F) is the first listed.
NCT01703702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01703702 about?
NCT01703702 is a clinical study titled "Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline". This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
What is the current status of trial NCT01703702?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 641 participants. The study started on 2012-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01703702?
The interventions under investigation include: florbetapir (18F) (DRUG).
Who is sponsoring clinical trial NCT01703702?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.